輕型和中間型β地中海貧血（兒科）
藥物誘導胎兒血紅蛋白合成
羥基脲治療
Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. （開啟新視窗）
來源: Hemoglobin 2014;38(1):44-8.
檢索: PubMed 24144212
DOI碼: 10.3109/03630269.2013.845844
Hydroxyurea in thalassemia intermedia--a promising therapy. （開啟新視窗）
來源: Ann Hematol 2005;84(7):441-6.
檢索: PubMed 15838670
DOI碼: 10.1007/s00277-005-1026-4
Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. （開啟新視窗）
來源: J Clin Pathol 2010;63(2):147-50.
檢索: PubMed 20154037
DOI碼: 10.1136/jcp.2009.070391
Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. （開啟新視窗）
來源: Eur J Haematol 2009;82(3):213-8.
檢索: PubMed 19077048
DOI碼: 10.1111/j.1600-0609.2008.01192.x
Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. （開啟新視窗）
來源: J Pediatr Hematol Oncol 2005;27(7):380-5.
檢索: PubMed 16012328
Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. （開啟新視窗）
來源: Eur J Haematol 2010;84(1):52-8.
檢索: PubMed 19799627
DOI碼: 10.1111/j.1600-0609.2009.01356.x
The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. （開啟新視窗）
來源: Pediatr Hematol Oncol 2003;20(6):429-34.
檢索: PubMed 14631615
Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. （開啟新視窗）
來源: Ann N Y Acad Sci 2005;1054:250-6.
檢索: PubMed 16339672
DOI碼: 10.1196/annals.1345.031
重組人促紅細胞生成素（單用或跟其他藥物聯合使用）
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. （開啟新視窗）
來源: Acta Haematol 2004;111(4):189-95.
檢索: PubMed 15153710
DOI碼: 10.1159/000077551
Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. （開啟新視窗）
來源: Eur J Haematol 2013;91(6):522-33.
檢索: PubMed 23927461
DOI碼: 10.1111/ejh.12182
Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. （開啟新視窗）
來源: Pediatr Ann 2008;37(5):339-46.
檢索: PubMed 18543545
Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. （開啟新視窗）
來源: Br J Haematol 1995;90(2):341-5.
檢索: PubMed 7794754
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. （開啟新視窗）
來源: Br J Haematol 2011;154(2):281-4.
檢索: PubMed 21496003
DOI碼: 10.1111/j.1365-2141.2011.08617.x
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. （開啟新視窗）
來源: Blood Rev 2012;26 Suppl 1:S35-9.
檢索: PubMed 22631042
DOI碼: 10.1016/S0268-960X(12)70011-5
其他製劑
Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. （開啟新視窗）
來源: Evid Based Complement Alternat Med 2009;6(2):141-51.
檢索: PubMed 18955291
DOI碼: 10.1093/ecam/nem139
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. （開啟新視窗）
來源: Br J Haematol 2013;161(4):587-93.
檢索: PubMed 23530969
DOI碼: 10.1111/bjh.12304
Butyric acid: what is the future for this old substance? （開啟新視窗）
來源: Swiss Med Wkly 2012;142:w13596.
檢索: PubMed 22674349
DOI碼: 10.4414/smw.2012.13596